AEZS vs. RVX, ATE, APS, HBP, MBX, BCT, VPH, WLLW, and CTX
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Resverlogix (RVX), Antibe Therapeutics (ATE), Aptose Biosciences (APS), Helix BioPharma (HBP), Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Valeo Pharma (VPH), Willow Biosciences (WLLW), and Crescita Therapeutics (CTX). These companies are all part of the "medical" sector.
Aeterna Zentaris (TSE:AEZS) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
In the previous week, Aeterna Zentaris' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.
Resverlogix received 302 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. However, 88.89% of users gave Aeterna Zentaris an outperform vote while only 84.01% of users gave Resverlogix an outperform vote.
0.8% of Aeterna Zentaris shares are owned by institutional investors. 4.0% of Aeterna Zentaris shares are owned by insiders. Comparatively, 43.2% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Resverlogix's return on equity of 0.00% beat Aeterna Zentaris' return on equity.
Resverlogix has lower revenue, but higher earnings than Aeterna Zentaris. Resverlogix is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
Aeterna Zentaris has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Resverlogix has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Summary
Aeterna Zentaris beats Resverlogix on 6 of the 11 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
